Am J Transplant, Volume 3, Suppl 5 Archives - Page 145 of 178 - ATC Abstracts

2013 American Transplant Congress
Critical Role of Notch-2 Signaling in Alloantibody Production
C. Magee, T. Shimizu, S. Ohori, C. Siebel, N. Najafian, L. Riella
Transplantation Research Center, Brigham & Women's Hospital, Harvard Medical School, Boston; Genentech, South San Francisco
The role of B cells in the alloimmune response is increasingly recognized, while alloantibody production remains a major barrier to the improvement of long-term graft…
2013 American Transplant Congress
Proteinkinase C Alpha Contributes to Impairment of Renal Blood Flow and Inflammation in Hypoxia Induced Renal Ischemia Reperfusion Injury (IRI)
D. Walacides, N. Rüskamp, R. Song, K. Hueper, M. Mengel, M. Meier, H. Haller, M. Schiffer, F. Gueler
Nephrology, Medical School Hannover, Hannover, Germany; Radiology, Medical School Hannover, Hannover, Germany; Applied Genomics Center, University of Alberta, Edmonton, Canada; Cental Animal Facility, Medical School Hannover, Hannover, Germany
Background – Renal ischemia reperfusion injury (IRI) leads to delayed graft function (DGF) after kidney transplantion and contributes to acute transplant rejection as well as…
2013 American Transplant Congress
Evidence for Renal Tubular Epithelial Cells as Another Source of IL-17 Producing Cells
H. Zhou, L. Xue, Y. Wang, J. Liu, L. Zhang, J. Yu
Urologic Diseases Center, The First Bethune Hospital, Jilin University, Changchun, Jilin, China; Key Laboratory of Pathobiology, Ministry of Education, School of Basic Medical Sciences, Jilin University, Changchun, Jilin, China; Urologic Surgery Department, Laigang Hospital,Taishan Medical University, Taishan, Shandong, China
Interleukin-17(IL-17) is mainly produced by a subset of CD4+T cells (TH17) .The exact source of IL-17 expression in renal graft during rejection remians unclear. A.Loverre…
2013 American Transplant Congress
Bilirubin Improvement Correlates with 90-Day Survival with Use of the ELAD® System in a Randomized, Controlled Study of Subjects with Acute Alcoholic Hepatitis or Acute Decompensation of Cirrhosis
L. Teperman, The ELAD Study Group
Mary Lea Johnson Richards Organ Transplantation Center, NYU SOM, New York, NY
Background: ELAD, a human cell-based liver support system, circulates ultrafiltrated patient plasma through a hollow fiber cartridge containing active immortalized C3A human liver cells. Studies…
2013 American Transplant Congress
Association between Early Progression in Chronic Kidney Disease Stage Following Liver Transplantation and Graft Survival
W. Irish, P. Massa, M. Tran, P. Bernhardt, J. Ricci
CTI Clinical Trial and Consulting Svcs, Raleigh; Novartis Pharmaceuticals Corporation, East Hanover; Novartis Pharma AG, Basel, Switzerland; Wellmera AG, Basel, Switzerland
Introduction: Renal dysfunction before and after liver transplantation is a significant predictor of graft survival (GS). This study aims to characterize the relationship between early…
2013 American Transplant Congress
Development of De Novo Anti-HLA Abs in Kidney Transplant Recipients: Final Analysis of the NIH CTOT02 Study
A. Chandraker, I. Guleria, D. Ikle, H. Chin, F. Vincenti, Y. Morrison, N. Bridges, W. Harmon, M. Sayegh
Brigham and Women's Hospital and Boston Children's Hospital, Harvard Medical School, Boston; RHO, Chapel Hill, NC; UCSF, San Francisco; NIH, Bethesda, MD
The NIH CTOT02 is the first large multi-center prospective study to examine the causes and effects of development of post-transplant de novo anti-HLA Ab in…
2013 American Transplant Congress
Favorable Post-Transplant Survival for Liver Transplant Recipients with Treated Porto_Pulmonary Hypertension
R. Salgia, N. Goodrich, R. Merion, P. Sharma
Division of Gastroenterology, University of Michigan, Ann Arbor, MI; Arbor Research Collaborative for Health, Ann Arbor; Surgery, University of Michigan, Ann Arbor
Background: Portopulmonary hypertension (PPH) was once considered an absolute contraindication for liver transplantation (LT) because of associated high peri- and postoperative mortality rates. With evolution…
2013 American Transplant Congress
Causes of Kidney Allograft Loss and Death in the United States, 2000-2010
J. Snyder, A. Matas, S. Leppke, A. Israni, B. Kasiske
Scientific Registry of Transplant Recipients, Minneapolis Medical Research Foundation, Minneapolis, MN; Department of Surgery, University of Minnesota, Minneapolis, MN
We sought to describe causes of kidney graft failure (GF) and death with function (DWF) by time posttransplant, and whether causes of immediate GF differed…
2013 American Transplant Congress
Geographic Heterogeneity in Use and Outcome of DCD Livers
W. Kim, P. Stock, H. Xiong, J. Liu, D. Schladt
Scientific Registry of Transplant Recipients, Minneapolis Medical Research Foundation, Minneapolis, MN; Gastroenterology, Mayo Clinic, Rochester, MN; Surgery, University of California San Francisco, San Francisco, CA
Background/Aim: Donation after circulatory death (DCD) liver transplants (LTs) are increasingly performed due to organ shortage. Graft survival rates for DCD LTs are inferior to…
2013 American Transplant Congress
Outcome on Renal Function of an Everolimus Based Therapy after Calcineurin Inhibitor Withdrawal in Maintenance Renal Transplant Recipients: 4 Year Data of the APOLLO Trial
K. Budde, C. Sommerer, P. Reinke, H. Haller, W. Arns, O. Witzke, B. Suwelack, C. May, D. Baeumer, E. Paulus, T. Rath
APOLLO Study Group, Germany; Novartis Pharma, Nuremberg, Germany
Objective: Assessment of renal function, safety and efficacy of an Everolimus (EVE) regimen after Calcineurin-Inhibitor (CNI) withdrawal in maintenance kidney allograft recipients.Methods: In an open-label,…